TTY Biopharm Company Limited reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 1,432.88 million compared to TWD 1,326.17 million a year ago. Net income was TWD 376.34 million compared to TWD 338.05 million a year ago. Basic earnings per share from continuing operations was TWD 1.51 compared to TWD 1.36 a year ago. Diluted earnings per share from continuing operations was TWD 1.51 compared to TWD 1.36 a year ago.
For the nine months, sales was TWD 3,860.78 million compared to TWD 3,528.81 million a year ago. Net income was TWD 923.71 million compared to TWD 849.72 million a year ago. Basic earnings per share from continuing operations was TWD 3.71 compared to TWD 3.42 a year ago. Diluted earnings per share from continuing operations was TWD 3.71 compared to TWD 3.41 a year ago.